Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks.
about
Control of Moderate-to-Severe Plaque Psoriasis with Efalizumab: 24-Week, Open-Label, Phase IIIb/IV Latin American Study Results.Cost effectiveness of home ultraviolet B phototherapy for psoriasis: economic evaluation of a randomised controlled trial (PLUTO study).Efficacy, effectiveness and safety of fumaric acid esters in the treatment of psoriasis: a systematic review of randomized and observational studies.Efficacy of Methotrexate in patients with plaque type psoriasisUltraviolet Phototherapy Management of Moderate-to-Severe Plaque Psoriasis: An Evidence-Based Analysis.Ustekinumab improves psoriasis without altering T cell cytokine production, differentiation, and T cell receptor repertoire diversity.The long-term efficacy and safety of new biological therapies for psoriasisUltraviolet B Phototherapy for Psoriasis: Review of Practical Guidelines.Fumaric acid esters for psoriasis: a systematic review.Metformin ameliorates methotrexate-induced hepatotoxicityEmerging drugs for psoriasis.Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolutionPolymeric nanoparticles-based topical delivery systems for the treatment of dermatological diseasesDo utilization management controls for phototherapy increase the prescription of biologics?Methotrexate-induced cutaneous ulceration in patients with erythrodermic mycosis fungoides.Home versus outpatient ultraviolet B phototherapy for mild to severe psoriasis: pragmatic multicentre randomised controlled non-inferiority trial (PLUTO study).Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study.Safety of conventional systemic agents and biologic agents in the treatment of psoriasis.Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis.The burden of moderate to severe psoriasis: an overview.Photoprotection in changing times - UV filter efficacy and safety, sensitization processes and regulatory aspects.Tofacitinib for the treatment of moderate-to-severe psoriasis.Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study.Current challenges and emerging drug delivery strategies for the treatment of psoriasis.A dermatologist guide to immunogenicityProinflammatory cytokine production in HaCaT cells treated by eosin: implications for the topical treatment of psoriasis.Effectiveness and safety of cyclosporine in pediatric plaque psoriasis: A multicentric retrospective analysis.Clinical efficacy of platelet rich plasma in combination with methotrexate in chronic plaque psoriatic patients.Severity of Psoriasis Differs Between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients.Effect of Oral PUVAsol on the Quality of Life in Indian Patients Having Chronic Plaque Psoriasis.Treatment of childhood psoriasis with phototherapy and photochemotherapy.What is the most common phototherapy prescription for psoriasis: NB-UVB or PUVA? Prescription behavior.The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study.Topical preparations for the treatment of psoriasis: results of a retrospective study over 15 years.Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry.Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial.Combination of efalizumab and acitretin in chronic plaque psoriasis.A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment.Effects of chronic retinoid administration on pituitary function.First-line systemic treatment of psoriasis: staying conventional or going biologic?
P2860
Q33588233-ABD2DD06-2B5A-4DE1-B35B-526A86574791Q33802843-515AD9F3-BC4D-40E2-844E-6C0C7FBF83ADQ34046298-B8B00534-1CC2-4BC4-A024-197931E46963Q34176219-CEBA2EEF-2F02-4310-8EC8-512256731DBCQ34449302-C6C02677-8B0E-4199-BBCB-51A11C9A98AAQ34517278-C424EBEA-5BFB-49F0-BD24-379D0C0BD670Q34613199-A99DFD21-B79B-447A-AB37-D2E24A4E704CQ35922839-3118011D-B530-4667-B3E0-8DAC4317FDECQ36043439-08D65F08-84D1-4F3C-883F-F66EC9B1FE3AQ36366019-65475306-3092-4EFC-9AD0-001613563D4CQ36634244-E10C2C36-5DE6-4F00-8389-D16A5986F74FQ36778450-B0FA8969-9C1B-4F86-BD7B-D4CD3FAE9270Q36780796-24C3E169-A2FE-463C-BBF1-E416018C7958Q36939785-9264FD7F-80CF-46F1-9917-71EAE415EC97Q37052855-D3547170-E2C2-499F-9EE2-83813B04E891Q37184480-B0E87F9A-C706-4F87-B809-A29D33F024BEQ37345488-851591DD-55C4-4261-8541-63EE7E34E149Q37607419-4684486E-EF85-4F4B-B3A4-9184445F9D73Q37929165-B59D7A20-5537-4225-BB2E-38B37F857E3EQ38044995-D02E4C38-F485-4072-AAE7-6CB40648F2BFQ38254382-18A56588-746F-4359-8FFC-6BA613E58AF6Q38349779-F3B8234C-4F1D-435F-BD3E-FCDBF6DD2E60Q38421550-143B0734-9A83-417B-9E36-DCD05CCAC23FQ38831055-794B837B-B543-4BF0-BCB4-86348CAA0A03Q39297511-5B80007D-1E3B-4CA9-A311-1D9D77239DF9Q39751988-F9AB6B02-ECF0-442D-9CC4-0E50FBB1F876Q40319405-C30FB3D9-4713-483D-91EC-94072EC127C1Q40389803-C59D18FA-2E58-45F9-A62E-82F6A53246F7Q40989242-09055B44-8306-4B0A-BE54-096A0DB1E0E5Q41889404-8F7D5C41-5C25-48EE-BBBE-2D73AFA14C19Q42541599-71071220-5413-4243-AA10-998E5E559B87Q43294646-89AD2FFF-9FC6-4823-97B7-049086231D65Q43760972-6B91AAC0-C996-4C00-9CF4-1A3348D4F359Q46527693-CEEE71D9-A083-4FB7-BD8D-5EB65FF0CCE4Q46553066-084F24CF-1856-4481-AD29-D0954BDFFE89Q46646221-56F0A713-83B9-4CAA-A62B-FD1DCDA5441BQ46797196-DF9F5427-0CFF-46FC-A8F7-D1966F97794CQ46887359-88833F9B-6339-43D4-A2CF-A65A5DF00215Q46948231-7DF2A5F4-5301-4619-B414-2B3AD0810572Q48156161-58F0DF0A-3716-480C-A060-840B4C3F8F65
P2860
Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Traditional therapies in the m ...... ent of the benefits and risks.
@ast
Traditional therapies in the m ...... ent of the benefits and risks.
@en
type
label
Traditional therapies in the m ...... ent of the benefits and risks.
@ast
Traditional therapies in the m ...... ent of the benefits and risks.
@en
prefLabel
Traditional therapies in the m ...... ent of the benefits and risks.
@ast
Traditional therapies in the m ...... ent of the benefits and risks.
@en
P2860
P1476
Traditional therapies in the m ...... ment of the benefits and risks
@en
P2093
P2860
P304
P356
10.1111/J.1365-2133.2005.06563.X
P407
P577
2005-04-01T00:00:00Z